Microbial deoxyribonucleic acid (DNA) (DNA)

Microbial deoxyribonucleic acid (DNA) in anaerobic bacteria and certain protozoa serves as the primary molecular target for the nitroimidazole class of anti-infective agents (StatPearls, 2023). In these specific organisms, the low-redox-potential environment facilitates the reductive activation of prodrugs, such as metronidazole, into highly reactive nitro radical intermediates (PubChem, CID 4168). These radicals interact directly with the DNA molecule, causing extensive strand breakage and destabilization of the double helix (NIH, 2023). This damage effectively halts DNA replication and transcription, leading to rapid microbial cell death. Because the reductive activation occurs primarily under anaerobic conditions, this target provides a high degree of selectivity for anaerobic pathogens while sparing aerobic host cells (Wikipedia, 2024). Resistance can emerge through mechanisms that decrease the reductive activation of the drug or through the expression of DNA-repair proteins (PubMed, PMID 11812466). Clinically, this target is exploited to treat a wide range of conditions, including intra-abdominal infections, trichomoniasis, and giardiasis. The interaction between the drug metabolites and the DNA is covalent and non-specific regarding the sequence, but highly specific regarding the metabolic state of the cell.

Other names

Bacterial DNAProtozoal DNAGenomic DNAMicrobial DNA

Reductive activation of nitroimidazole prodrugs by microbial electron transport proteins (e.g., ferredoxin) generates reactive nitro radical anions that cause covalent binding to DNA, resulting in DNA strand breakage and inhibition of nucleic acid synthesis (StatPearls, 2023; PubChem, CID 4168).